Xinrui Pharmaceuticals (06108.HK) announced that on May 28, 2024, China Xinrui (a wholly-owned subsidiary of the company, as an investor) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group, CITIC Securities (Hong Kong) Co., Ltd. and CITIC Lyon Securities Co., Ltd. Based on this, China Xinrui has agreed to subscribe for investors' shares at the sale price. The total investment in investors' shares is HK$12 million.
新锐医药(06108.HK)附属作为基石投资者认购1200万港元的一脉阳光股份
A subsidiary of Xinrui Pharmaceuticals (06108.HK) subscribed HK$12 million in Yimai Sunshine shares as a cornerstone investor
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated